
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-Q

(Mark One)



**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended July 1, 2006

OR



**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission file number: 0-21116

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction
of incorporation or organization)

87-0500306

(I.R.S. Employer
Identification No.)

3838 West Parkway Blvd., Salt Lake City, Utah 84120

(Address of principal executive offices, Zip Code)

(801) 954-7100

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated
filer

Accelerated filer

Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares outstanding of the registrant's common stock as of August 3, 2006 was 17,803,855.

USANA HEALTH SCIENCES, INC.

FORM 10-Q

For the Quarterly Period Ended July 1, 2006

INDEX

[PART I. FINANCIAL INFORMATION](#)

[Item 1](#)

[Financial Statements](#)

[Consolidated Balance Sheets](#)

[Consolidated Statements of Earnings—Quarter Ended](#)
[Consolidated Statements of Earnings—Six Months Ended](#)
[Consolidated Statement of Stockholders' Equity and Comprehensive Income](#)
[Consolidated Statements of Cash Flows](#)
[Notes to Consolidated Financial Statements](#)

[Item 2](#) [Management's Discussion and Analysis of Financial Condition and Results of Operations](#)
[Item 3](#) [Quantitative and Qualitative Disclosures About Market Risk](#)
[Item 4](#) [Controls and Procedures](#)

PART II. OTHER INFORMATION

[Item 1A](#) [Risk Factors](#)
[Item 2](#) [Unregistered Sales of Equity Securities and Use of Proceeds](#)
[Item 4](#) [Submission of Matters to a Vote of Security Holders](#)
[Item 6](#) [Exhibits](#)

[Signatures](#)

2

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands)

	<u>December 31, 2005</u>	<u>July 1, 2006 (unaudited)</u>
ASSETS		
Current assets		
Cash and cash equivalents	\$ 10,579	\$ 9,173
Inventories	22,223	20,458
Prepaid expenses and other current assets	6,024	6,048
Deferred income taxes	3,004	2,532
Total current assets	<u>41,830</u>	<u>38,211</u>
Property and equipment, net	23,302	23,777
Goodwill	5,690	5,690
Other assets	2,886	2,612
	<u>\$ 73,708</u>	<u>\$ 70,290</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable	\$ 4,955	\$ 6,303
Other current liabilities	21,601	24,479
Total current liabilities	<u>26,556</u>	<u>30,782</u>
Long-term liabilities	1,414	69
Stockholders' equity		
Common stock, \$0.001 par value; authorized 50,000 shares, issued and outstanding 18,343 as of December 31, 2005 and 17,723 as of July 1, 2006	18	18
Additional paid-in capital	9,161	7,420
Retained earnings	35,720	31,211
Accumulated other comprehensive income	839	790
Total stockholders' equity	<u>45,738</u>	<u>39,439</u>
	<u>\$ 73,708</u>	<u>\$ 70,290</u>

The accompanying notes are an integral part of these statements.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(in thousands, except per share data)
(unaudited)

	<u>Quarter Ended</u>	
	<u>July 2, 2005</u>	<u>July 1, 2006</u>
Net sales	\$ 82,015	\$ 93,911
Cost of sales	<u>19,499</u>	<u>22,276</u>
Gross profit	62,516	71,635
Operating expenses:		
Associate incentives	31,911	37,454
Selling, general and administrative	15,168	17,991
Research and development	<u>689</u>	<u>830</u>
Total operating expenses	<u>47,768</u>	<u>56,275</u>
Earnings from operations	14,748	15,360
Other income (expense):		
Interest income	93	169
Interest expense	(3)	(10)
Other, net	<u>(157)</u>	<u>177</u>
Other income (expense), net	<u>(67)</u>	<u>336</u>
Earnings before income taxes	14,681	15,696
Income taxes	<u>5,138</u>	<u>5,352</u>
Net earnings	<u>\$ 9,543</u>	<u>\$ 10,344</u>
Earnings per common share		
Basic	\$ 0.50	\$ 0.57
Diluted	\$ 0.48	\$ 0.55
Weighted average common shares outstanding		
Basic	18,948	18,149
Diluted	19,821	18,777

The accompanying notes are an integral part of these statements.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(in thousands, except per share data)
(unaudited)

	<u>Six Months Ended</u>	
	<u>July 2, 2005</u>	<u>July 1, 2006</u>
Net sales	\$ 158,593	\$ 183,562
Cost of sales	<u>37,509</u>	<u>43,614</u>

Gross profit	121,084	139,948
Operating expenses:		
Associate incentives	61,461	72,882
Selling, general and administrative	30,017	35,617
Research and development	1,288	1,562
Total operating expenses	92,766	110,061
Earnings from operations	28,318	29,887
Other income (expense):		
Interest income	197	311
Interest expense	(3)	(10)
Other, net	(96)	330
Other income, net	98	631
Earnings before income taxes	28,416	30,518
Income taxes	9,945	10,614
Net earnings	\$ 18,471	\$ 19,904
Earnings per common share		
Basic	\$ 0.97	\$ 1.09
Diluted	\$ 0.93	\$ 1.05
Weighted average common shares outstanding		
Basic	19,008	18,304
Diluted	19,896	19,002

The accompanying notes are an integral part of these statements.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME

Six Months Ended July 2, 2005 and July 1, 2006

(in thousands)

(unaudited)

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
	Shares	Value				
For the Six Months Ended July 2, 2005						
Balance at January 1, 2005	18,953	\$ 19	\$ 11,853	\$ 34,496	\$ 1,475	\$ 47,843
Comprehensive income						
Net earnings	—	—	—	18,471	—	18,471
Foreign currency translation adjustment, net	—	—	—	—	(740)	(740)
Comprehensive income						17,731
Common stock retired	(353)	—	(3,948)	(11,053)	—	(15,001)
Common stock issued under equity- based award plan, including tax benefit of \$2,679	216	—	4,230	—	—	4,230
Balance at July 2, 2005	18,816	\$ 19	\$ 12,135	\$ 41,914	\$ 735	\$ 54,803

For the Six Months Ended July 1, 2006

Balance at December 31, 2005	18,343	\$	18	\$	9,161	\$	35,720	\$	839	\$	45,738
Comprehensive income											
Net earnings	—		—		—		19,904		—		19,904
Foreign currency translation adjustment, net	—		—		—		—		(49)		(49)
Comprehensive income											19,855
Common stock retired	(801)		—		(5,733)		(24,413)		—		(30,146)
Equity-based compensation expense	—		—		2,152		—		—		2,152
Common stock issued under equity-based award plan, including tax benefit of \$1,033	181		—		1,840		—		—		1,840
Balance at July 1, 2006	<u>17,723</u>	<u>\$</u>	<u>18</u>	<u>\$</u>	<u>7,420</u>	<u>\$</u>	<u>31,211</u>	<u>\$</u>	<u>790</u>	<u>\$</u>	<u>39,439</u>

The accompanying notes are an integral part of these statements.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	<u>Six Months Ended</u>	
	<u>July 2, 2005</u>	<u>July 1, 2006</u>
Increase (decrease) in cash and cash equivalents		
Cash flows from operating activities		
Net earnings	\$ 18,471	\$ 19,904
Adjustments to reconcile net earnings to net cash provided by operating activities		
Depreciation and amortization	2,824	2,924
Loss on sale of property and equipment	5	8
Equity-based compensation expense	—	2,152
Excess tax benefit from equity-based payment arrangements	—	(832)
Deferred income taxes	56	(721)
Allowance for inventory valuation	43	1,690
Changes in operating assets and liabilities:		
Inventories	(4,545)	340
Prepaid expenses and other assets	(734)	(411)
Accounts payable	(261)	1,379
Other current liabilities	6,105	3,805
Total adjustments	<u>3,493</u>	<u>10,334</u>
Net cash provided by operating activities	<u>21,964</u>	<u>30,238</u>
Cash flows from investing activities		
Proceeds from the sale of property and equipment	4	—
Purchases of property and equipment	(2,688)	(3,104)
Net cash used in investing activities	<u>(2,684)</u>	<u>(3,104)</u>
Cash flows from financing activities		
Proceeds from exercise of equity-based awards	1,551	807
Excess tax benefit from equity-based payment arrangements	—	832
Redemption of common stock	(15,001)	(30,146)
Net cash used in financing activities	<u>(13,450)</u>	<u>(28,507)</u>
Effect of exchange rate changes on cash and cash equivalents	(469)	(33)
Net increase (decrease) in cash and cash equivalents	<u>5,361</u>	<u>(1,406)</u>
Cash and cash equivalents, beginning of period	<u>15,067</u>	<u>10,579</u>

Cash and cash equivalents, end of period	<u>\$ 20,428</u>	<u>\$ 9,173</u>
--	------------------	-----------------

Supplemental disclosures of cash flow information

Cash paid during the period for:

Interest	\$ 3	\$ 8
Income taxes	5,944	10,491

The accompanying notes are an integral part of these statements.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Basis of Presentation

The unaudited interim consolidated financial information of USANA Health Sciences, Inc. and Subsidiaries (the “Company” or “USANA”) has been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying interim consolidated financial information contains all adjustments, consisting of normal recurring adjustments, necessary to present fairly the Company’s financial position as of July 1, 2006, and results of operations for the quarters and six months ended July 2, 2005 and July 1, 2006. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005. The results of operations for the quarter and six months ended July 1, 2006 may not be indicative of the results that may be expected for the fiscal year ending December 30, 2006.

Recently Issued Accounting Standards

In June 2006, the FASB issued FIN No. 48, *Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109* (“FIN 48”), which clarifies the accounting for uncertainty in income tax positions. FIN 48 defines the threshold for recognizing tax return positions in the financial statements as “more likely than not” that the position is sustainable, based on its technical merits. FIN 48 also provides guidance on the measurement, classification and disclosure of tax return positions in the financial statements. FIN 48 is effective for the first reporting period beginning after December 15, 2006, with the cumulative effect of the change in accounting principle recorded as an adjustment to the beginning balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of adopting FIN 48 on its consolidated financial statements.

NOTE A—EQUITY-BASED COMPENSATION

Effective January 1, 2006, the Company adopted the provisions of Statement of Financial Accounting Standards (“SFAS”) No. 123(R), “Share-Based Payment,” using the modified version of prospective application. Under this method, compensation expense includes the estimated fair value of equity awards vested during the reported periods. Expense for equity awards vested is determined based on grant date fair value previously calculated for pro forma disclosures under SFAS No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure—An Amendment of FASB Statement No. 123.” Equity-based compensation expense recognized for the quarter and six months ended July 1, 2006 was comprised as follows:

	<u>Quarter Ended July 1, 2006</u>	<u>Six Months Ended July 1, 2006</u>
Cost of sales	\$ 143	\$ 270
Selling, general and administrative	930	1,637
Research and development	132	245
	<u>\$ 1,205</u>	<u>\$ 2,152</u>

July 1, 2006, can be found in the pro forma table in this footnote. The Company currently estimates that equity-based compensation expense will reduce basic and diluted earnings per share in 2006 by \$0.18. The following table shows remaining unrecognized compensation expense on a pre-tax basis related to all types of nonvested equity awards outstanding as of July 1, 2006. This table does not include an estimate for future grants that may be issued.

Remainder of 2006	\$ 2,578
2007	5,095
2008	4,718
2009	2,840
2010	2,203
Thereafter	412
	<u>\$17,846</u>

The cost above is expected to be recognized over a weighted-average period of 2.4 years.

Prior to the adoption of SFAS No. 123(R), the Company presented all tax benefits resulting from equity-based compensation as cash flows from operating activities in the condensed consolidated statements of cash flows. SFAS No. 123(R) requires cash flows resulting from tax deductions in excess of the grant-date fair value of equity awards to be included in cash flows from financing activities. The excess tax benefits of \$832 related to equity-based compensation included in cash flows from financing activities in the first six months of 2006 would have been included in cash flows from operating activities if the Company had not adopted SFAS No. 123(R).

As permitted by SFAS No. 148, prior to the adoption of SFAS No. 123(R) the Company accounted for equity award expense under the recognition and measurement principles of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," under which no compensation was recognized in the Company's financial statements for the quarter and six months ended July 2, 2005. In connection with the modified prospective method, disclosures made for periods prior to the adoption of SFAS No. 123(R) do not reflect restated amounts.

The following table presents equity-based compensation expense included in our financial statements for the quarter and six months ended July 1, 2006, and also illustrates the pro forma effects on net earnings and earnings per share as if the Company had applied the fair value recognition provisions of SFAS No. 123, as amended by SFAS No. 148, to equity-based compensation for the quarter and six months ended July 2, 2005:

		<u>Quarter Ended</u>		<u>Six Months Ended</u>	
		<u>July 2, 2005</u>	<u>July 1, 2006</u>	<u>July 2, 2005</u>	<u>July 1, 2006</u>
Net earnings	As reported	\$ 9,543	\$ 10,344	\$ 18,471	\$ 19,904
Add: Compensation cost included in reported net income		—	819	—	1,504
Deduct: Total compensation expense under the fair value method for all awards		(466)	(819)	(914)	(1,504)
Net earnings	Pro forma	<u>\$ 9,077</u>	<u>\$ 10,344</u>	<u>\$ 17,557</u>	<u>\$ 19,904</u>
Earnings per share—basic	As reported	<u>\$ 0.50</u>	<u>\$ 0.57</u>	<u>\$ 0.97</u>	<u>\$ 1.09</u>
	Pro forma	<u>\$ 0.48</u>	<u>\$ 0.57</u>	<u>\$ 0.92</u>	<u>\$ 1.09</u>
Earnings per share—diluted	As reported	<u>\$ 0.48</u>	<u>\$ 0.55</u>	<u>\$ 0.93</u>	<u>\$ 1.05</u>
	Pro forma	<u>\$ 0.46</u>	<u>\$ 0.55</u>	<u>\$ 0.88</u>	<u>\$ 1.05</u>

The Company's 2006 Equity Incentive Award Plan (2006 Plan), which was approved by the shareholders at the Annual Shareholders' Meeting held on April 19, 2006, allows for the grant of various equity awards including stock options, stock-settled stock appreciation rights, deferred stock units, and other types of equity-based awards to the Company's officers, key employees, and non-employee directors. Prior to the approval of the 2006 Plan, the Company maintained the 2002 Stock Option Plan (2002 Plan), which was limited to the granting of incentive and non-qualified stock options. Between January 1, 2006, and April 19, 2006, the Company issued 175 stock options under the 2002 Plan. Options granted under the 2002 Plan generally vest 20% each year on the anniversary of the grant date and expire five to ten years from the date of grant. The 2006 Plan replaces the 2002 Plan for all future grants, and no new awards will be granted under the 2002 Plan. The 2006 Plan authorized 5,000 shares of common stock for issuance, of which 4,704 shares were available for future issuance as of July 1, 2006. Of the 296 shares granted under the 2006 Plan, 290 were stock-settled stock appreciation rights, 3 were stock options, and 3 were deferred stock units. The Company's Compensation Committee has initially determined that awards to be granted to officers and key employees under the 2006 Plan will generally vest 20% each year on the anniversary of the grant date and expire five to five and one-half years from the date of grant. Awards of stock options and stock-settled stock appreciation rights to be granted to non-employee directors will generally vest 25% each quarter commencing on the last day of the fiscal quarter in which the awards are granted, and will expire five years from the date of grant. Awards of deferred stock units are full-value shares at the date

of grant, vesting in connection with service period, and do not have expiration dates.

The Company continues to use the Black-Scholes option pricing model to estimate fair value of equity awards, which requires the input of highly subjective assumptions, including the expected stock price volatility. Prior to the implementation of SFAS No. 123(R), expected volatility represented the historical share prices of the Company's common stock over the expected life of the award and the risk-free interest rate was based on the U.S. Treasury yield curve on the date of grant with respect to the expected life of the award. Expected life was based on the contractual term of the award.

Preceding the adoption of SFAS No. 123(R), the Company engaged a third-party valuation expert to analyze assumptions used by the Company and to determine changes necessary for a more accurate reflection of the estimated fair value of equity

10

awards granted by the Company. Based on this analysis the Company decided that, effective January 1, 2006, expected volatility will be calculated by averaging the historical volatility of the Company and a peer group index. The risk-free interest rate will continue to be based on the U.S. Treasury yield curve on the date of grant with respect to the expected life of the award. Also, effective January 1, 2006, due to the "plain vanilla" characteristics of the Company's stock options, the simplified method, as permitted by the guidance provided in Staff Accounting Bulletin No. 107, will be used to determine expected life while permitted. We estimate that the equity-based compensation expense included in earnings before income taxes for the six months ended July 1, 2006 was decreased by approximately \$128 due to the above mentioned change in assumptions used to estimate fair value of awards granted during the six months ended July 1, 2006.

The following table includes weighted-average assumptions used to calculate the fair value of awards granted during the periods indicated, as well as the weighted-average fair value of awards granted. Deferred stock units are full-value shares at the date of grant and have been excluded from the table below.

	Quarter Ended		Six Months Ended	
	July 2, 2005	July 1 2006	July 2 2005	July 1 2006
Expected volatility	72.00%	57.04%	72.00%	57.04%
Risk-free interest rate	3.87%	4.98%	3.87%	4.79%
Expected life	5.25 yrs.	4.125 yrs.	5.25 yrs.	4.125 yrs.
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Weighted-average fair value of awards granted	\$ 26.84	\$ 18.59	\$ 26.84	\$ 18.80

The weighted-average fair value and grant price of the 3 deferred stock units granted during the quarter and six months ended July 1, 2006 was \$37.60.

A summary of the Company's stock option and stock-settled stock appreciation right activity for the six months ended July 1, 2006 is as follows:

	Shares	Weighted-average Exercise Price*	Weighted-average Remaining Contractual Term	Aggregate Intrinsic Value**
Outstanding at December 31, 2005	1,773	\$ 17.43	6.97	\$ 37,121
Granted	468	\$ 38.14	—	\$ —
Exercised	(181)	\$ 4.47	—	\$ —
Canceled or expired	—	\$ —	—	\$ —
Outstanding at July 1, 2006	2,060	\$ 23.26	6.05	\$ 31,186
Exercisable at July 1, 2006	589	\$ 26.16	7.69	\$ 7,472

* All awards are granted at the market value on the date of grant, which is established by averaging the closing price of the Company's common stock over the five trading days preceding the date of grant.

** Aggregate intrinsic value is defined as the difference between the current market value and the exercise price of awards that were in-the-money, and is estimated using the closing price of the Company's common stock on the last trading day of periods ended as of the dates indicated.

Total intrinsic value of awards exercised, which includes stock options and stock-settled stock appreciation rights, during the six month periods ending July 2, 2005 and July 1, 2006, was \$7,284 and \$6,348, respectively.

11

A summary of the Company's deferred stock unit activity for the six months ended July 1, 2006 is as follows:

	Shares	Weighted- average Fair Value
Nonvested at December 31, 2005	—	\$ —
Granted	3	\$ 37.60
Vested	(1)	\$ 37.60
Canceled or expired	—	\$ —
Nonvested at July 1, 2006	<u>2</u>	<u>\$ 37.60</u>

The total fair value of awards vested during the six month periods ending July 2, 2005 and July 1, 2006, which includes stock options, stock-settled stock appreciation rights, and deferred stock units, was \$2,383 and \$2,561, respectively.

NOTE B—INVENTORIES

Inventories consist of the following:

	December 31, 2005	July 1, 2006
Raw materials	\$ 11,878	\$ 10,676
Work in progress	3,533	2,734
Finished goods	9,482	10,040
	<u>24,893</u>	<u>23,450</u>
Less allowance for inventory valuation	2,670	2,992
	<u>\$ 22,223</u>	<u>\$ 20,458</u>

NOTE C—PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

	December 31, 2005	July 1, 2006
Prepaid expenses	\$ 2,038	\$ 1,337
Miscellaneous receivables, net	3,537	3,499
Other current assets	449	1,212
	<u>\$ 6,024</u>	<u>\$ 6,048</u>

NOTE D—PROPERTY AND EQUIPMENT

Cost of property and equipment and their estimated useful lives is as follows:

	Years	December 31, 2005	July 1, 2006
Building	40	\$ 10,377	\$ 10,347
Laboratory and production equipment	5-7	9,706	10,231
Sound and video library	5	600	600
Computer equipment and software	3-5	23,083	23,549
Furniture and fixtures	3-5	2,654	2,669
Automobiles	3-5	248	221
Leasehold improvements	3-5	2,709	2,742
Land improvements	15	931	931
		<u>50,308</u>	<u>51,290</u>
Less accumulated depreciation and amortization		29,605	31,814
		<u>20,703</u>	<u>19,476</u>
Land		2,064	2,066
Deposits and projects in process		535	2,235
		<u>\$ 23,302</u>	<u>\$ 23,777</u>

NOTE E—GOODWILL

Goodwill represents the excess of the purchase price paid for acquired entities over the fair market value of the net assets acquired. As of July 1, 2006, goodwill totaled \$5,690, comprising \$4,267 that was associated with the July 1, 2003 acquisition of Wasatch Product Development, Inc. (WPD) and \$1,423 that was associated with the February 1, 2004 acquisition of FMG. No events have occurred subsequent to either acquisition that have resulted in an impairment of the original goodwill amounts initially recorded from the transactions. In accordance with SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill must be tested at least annually and if the carrying amount of goodwill exceeds its fair value, an impairment loss must be recognized in an amount equal to that excess.

There were no changes in the carrying amount of goodwill for the acquired subsidiaries for the six months ended July 1, 2006:

	<u>WPD</u>	<u>FMG</u>	<u>Consolidated Total</u>
Balance at December 31, 2005	\$ 4,267	\$ 1,423	\$ 5,690
Goodwill acquired	—	—	—
Impairment adjustments	—	—	—
Balance at July 1, 2006	<u>\$ 4,267</u>	<u>\$ 1,423</u>	<u>\$ 5,690</u>

13

NOTE F—OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	<u>December 31, 2005</u>	<u>July 1, 2006</u>
Associate incentives	\$ 3,528	\$ 4,592
Accrued employee compensation	6,257	4,435
Income taxes	2,429	2,446
Sales taxes	2,354	2,093
Associate promotions	616	1,937
Unearned revenue	1,903	3,307
Provision for returns and allowances	943	883
All other	3,571	4,786
	<u>\$ 21,601</u>	<u>\$ 24,479</u>

NOTE G—COMMON STOCK AND EARNINGS PER SHARE

Basic earnings per share are based on the weighted average number of shares outstanding for each period. Weighted-average shares issued and weighted-average shares redeemed during the periods indicated have been included in the calculation of weighted-average shares outstanding for basic earnings per share. Diluted earnings per common share are based on shares outstanding (computed under basic EPS) and potentially dilutive shares. Shares included in diluted earnings per share calculations include stock options granted that are in the money but have not yet been exercised.

	<u>For the Quarter Ended</u>	
	<u>July 2, 2005</u>	<u>July 2, 2006</u>
Earnings available to common shareholders	<u>\$ 9,543</u>	<u>\$ 10,344</u>
Basic EPS		
Shares		
Common shares outstanding entire period	18,953	18,343
Weighted average common shares:		
Issued during period	211	173
Canceled during period	(216)	(367)
Weighted average common shares outstanding during period	<u>18,948</u>	<u>18,149</u>
Earnings per common share—basic	<u>\$ 0.50</u>	<u>\$ 0.57</u>
Diluted EPS		
Shares		
Weighted average shares outstanding during period—basic	18,948	18,149
Dilutive effect of stock options	873	628
Weighted average shares outstanding during period—diluted	<u>19,821</u>	<u>18,777</u>
Earnings per common share—diluted	<u>\$ 0.48</u>	<u>\$ 0.55</u>

14

Options to purchase 571 shares of stock were not included in the computation of EPS for the quarter ended July 1, 2006 due to their exercise price being greater than the average market price of the shares.

	For the Six Months Ended	
	July 2, 2005	July 1 2006
Earnings available to common shareholders	\$ 18,471	\$ 19,904
Basic EPS		
Shares		
Common shares outstanding entire period	18,953	18,343
Weighted average common shares:		
Issued during period	163	144
Canceled during period	(108)	(183)
Weighted average common shares outstanding during period	19,008	18,304
Earnings per common share—basic	\$ 0.97	\$ 1.09
Diluted EPS		
Shares		
Weighted average shares outstanding during period—basic	19,008	18,304
Dilutive effect of equity-based awards	888	698
Weighted average shares outstanding during period—diluted	19,896	19,002
Earnings per common share—diluted	\$ 0.93	\$ 1.05

Options to purchase 319 shares of stock were not included in the computation of EPS for the six months ended July 1, 2006 due to their exercise price being greater than the average market price of the shares.

During the six months ended July 2, 2005, and July 1, 2006, the Company expended \$15,001, and \$30,146 to purchase 353 and 801 shares, respectively, under the Company's share repurchase plan. The purchase of shares under this plan reduces the number of shares issued and outstanding.

NOTE H—SEGMENT INFORMATION

The Company's operations are distinguished by regions served and method of distribution employed. Two reportable business segments are recognized by the Company: Direct Selling and Contract Manufacturing. These operating segments are evaluated regularly by management in determining the allocation of resources and in assessing the performance of the Company. Management evaluates performance based on net sales and the amount of operating income or loss. Segment profit or loss is based on profit or loss from operations before income taxes. All intercompany transactions, intercompany profit, currency gains and losses, interest income and expense, and income taxes are excluded in the Company's determination of segment profit or loss.

Direct Selling

The Company's Direct Selling segment develops, manufactures, and distributes nutritional, weight management, and personal care products, and is the primary segment in which the Company operates. Products are distributed through a network marketing system using independent distributors referred to as "Associates." Products are also sold directly to "Preferred Customers," who purchase products for personal use and are not permitted to resell or distribute the products.

Selected financial information for the Direct Selling segment is reported for two geographic regions: North America and Pacific Rim. North America includes the United States, Canada, and Mexico. All other entities outside of North America are located within the Pacific Rim region, which includes Australia-New Zealand, Hong Kong, Japan, Taiwan, South Korea, and Singapore.

The profitability of each reported region within the Direct Selling segment is representative of what is controllable within that region by local management and is not necessarily indicative of actual profit or loss generated by a fully burdened region. However, the presentation of the data is consistent with how management evaluates each region and the respective markets within that region.

Contract Manufacturing

Operating activities for the Contract Manufacturing segment primarily exist for the production of the Company's Sensé™ line of

skin and personal care products. In addition to the production of the Sensé product line, contract manufacturing services are provided to a limited number of external customers. This segment includes operations located in Draper, Utah and at a facility in Tianjin, China, which the Company acquired in October 2005. Manufacturing and packaging activities for the Company's Sensé products began at the Draper, Utah facility during the fourth quarter of 2003. In the second quarters of 2005 and 2006, we had one and two external customers, respectively, that accounted for more than ten percent of segment sales.

Financial information summarized by operating segment and geographic region for the quarters ended July 2, 2005 and July 1, 2006 is listed below:

	Net Sales from External Customers	Inter-segment Revenues	Earnings before Income Taxes
Quarter ended July 2, 2005:			
Direct Selling			
North America	\$ 52,264	\$ 15,316	\$ 7,444
Pacific Rim	27,548	1,382	7,068
Segment Total	79,812	16,698	14,512
Contract Manufacturing	2,203	1,796	221
Reportable Segments Total	82,015	18,494	14,733
Unallocated and Other *	—	(18,494)	(52)
Consolidated Total	\$ 82,015	\$ —	\$ 14,681

16

	Net Sales from External Customers	Inter-segment Revenues	Earnings before Income Taxes
Quarter ended July 1, 2006:			
Direct Selling			
North America	\$ 62,201	\$ 16,651	\$ 7,917
Pacific Rim	28,876	1,402	8,484
Segment Total	91,077	18,053	16,401
Contract Manufacturing	2,834	1,236	(97)
Reportable Segments Total	93,911	19,289	16,304
Unallocated and Other *	—	(19,289)	(608)
Consolidated Total	\$ 93,911	\$ —	\$ 15,696

Financial information summarized by operating segment and geographic region for the six months ended July 2, 2005 and July 1, 2006 is listed below:

	Net Sales from External Customers	Inter-segment Revenues	Earnings before Income Taxes	Long-lived Assets	Total Assets
Six months ended July 2, 2005:					
Direct Selling					
North America	\$ 101,522	\$ 33,251	\$ 14,419	\$ 22,426	\$ 68,688
Pacific Rim	52,939	2,659	12,714	2,909	18,778
Segment Total	154,461	35,910	27,133	25,335	87,466
Contract Manufacturing	4,132	3,871	772	6,361	12,720

Reportable Segments Total	158,593	39,781	27,905	31,696	100,186
Unallocated and Other *	—	(39,781)	511	39	(18,368)
Consolidated Total	\$ 158,593	\$ —	\$ 28,416	\$ 31,735	\$ 81,818

17

	Net Sales from External Customers	Inter-segment Revenues	Earnings before Income Taxes	Long-lived Assets	Total Assets
Six months ended July 1, 2006:					
Direct Selling					
North America	\$ 122,335	\$ 32,666	\$ 16,260	\$ 21,864	\$ 41,190
Pacific Rim	55,495	2,643	14,405	2,681	13,780
Segment Total	177,830	35,309	30,665	24,545	54,970
Contract Manufacturing	5,732	2,325	(181)	7,531	12,892
Reportable Segments Total	183,562	37,634	30,484	32,076	67,862
Unallocated and Other *	—	(37,634)	34	3	2,428
Consolidated Total	\$ 183,562	\$ —	\$ 30,518	\$ 32,079	\$ 70,290

* “Unallocated and Other” includes certain corporate items and eliminations that are not allocated to the operating segments.

NOTE I—SUBSEQUENT EVENTS

On July 26, 2006, we announced that our Board of Directors authorized an additional dollar amount for the repurchase of our outstanding shares of \$40,000, increasing the total authorized amount to \$50,654.

18

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of USANA’s financial condition and results of operations should be read in conjunction with the Unaudited Consolidated Financial Statements and Notes contained in this quarterly report.

General

USANA Health Sciences, Inc. develops and manufactures high-quality nutritional, weight management, and personal care products. We market our products on the basis of high levels of bioavailability, safety, and quality. We distribute our products through a network marketing system using independent distributors whom we refer to as “Associates.” As of July 1, 2006, we had 142,000 active Associates worldwide. We also sell products directly to “Preferred Customers” who purchase products for personal use and are not permitted to resell or distribute the products. As of July 1, 2006, we had 75,000 active Preferred Customers worldwide. The majority of sales in the Direct Selling segment come from Associates. For the six months ended July 1, 2006, sales to Associates accounted for approximately 86% of net sales for the Direct Selling segment. For purposes of this report, we only count as active customers those Associates and Preferred Customers who have purchased product from USANA at any time during the most recent three-month period.

The fiscal year end of USANA is the Saturday closest to December 31 of each year. Fiscal year 2005 ended on December 31, 2005, and fiscal year 2006 will end on December 30, 2006.

As discussed more fully in Note H — Segment Information to the consolidated financial statements, we have two reportable segments: Direct Selling and Contract Manufacturing. The Direct Selling segment constitutes our principal line of business: developing, manufacturing, and distributing nutritional and personal care products through a network marketing system. The Contract Manufacturing segment primarily consists of manufacturing and packaging the Company’s Sense™ product line of skin and personal care products, but also includes contract manufacturing services provided to a limited number of third-party customers.

Our primary product lines within the Direct Selling segment consist of USANA[®] Nutritionals and Sense — beautiful

science^â (Sensé). The USANA^â Nutritionals product line is further categorized into three separate classifications: Essentials, Optimizers, and Macro Optimizers. Additionally, we offer combination packs, which generally contain a variety of products from each product line.

USANA^â Nutritionals.

The Essentials include core vitamin and mineral supplements that provide a foundation of advanced nutrition for every age group. To help meet the “essential” nutrient needs of children and teens during the years of development, when good nutrition is especially important, USANA offers: Usanimals^Ô, a formulation of vitamins, minerals, and antioxidants, in an easy-to-take chewable tablet for children 13 months to 12 years old; and Body Rox^Ô, a nutritional supplement containing 31 essential vitamins, minerals, antioxidants, and cofactors for adolescents 12 to 18 years old. USANA^â Essentials for adults is a combination of two products: Mega Antioxidant, a balanced, high-potency blend of 30 vitamins, antioxidants, and other important nutrients to support cellular metabolism and to counteract free-radical damage; and Chelated Mineral, a complete spectrum of essential minerals, in balanced, highly bioavailable forms. The USANA^â Essentials are also available in a convenient pillow pack format, HealthPak 100^Ô.

The Optimizers are more targeted supplements designed to meet individual health and nutritional needs. Products in this category include Proflavanol^â, Poly C^â, Procosa^â II, CoQuinone^â 30, BiOmega-3^Ô, E-Prime^Ô, Active Calcium^Ô, Active Calcium^Ô Chewable, PhytoEstrin^Ô, Palmetto Plus^Ô, Ginkgo-PS^Ô, Garlic EC^Ô, Visionex^â, OptOmega^â, and Hepasil DTXTM.

The Macro Optimizers include healthy, low-glycemic convenience foods and other related products. Nutrimeal^Ô, Fibergy^â, and SoyaMax^Ô drink mixes, and Nutrition and Fibergy BarsTM are included in this product category. This product line also includes our RESETTM Weight Management Program designed to assist in a long-term change in diet, and the accompanying

RESETTM kit. The RESET kit is conveniently packaged in a self-contained box with the USANA products needed to complete a five-day regimen, designed to assist in losing weight and providing a start to a long-term change in diet.

Sensé - beautiful science^â

The SenséTM product line includes premium, science-based personal care products that support healthy skin and hair by providing advanced topical nourishment, moisturization, and protection. These products are produced with our patent-pending, self-preserving technology. This technology uses a unique blend of botanicals, antioxidants, and active ingredients to keep products fresh, without adding traditional chemical preservatives. Products in this line include Perfecting Essence, Gentle Daily Cleanser, Hydrating Toner, Daytime Protective Emulsion, Eye Nourisher, Night Renewal, Serum Intensive, Rice Bran Polisher, Revitalizing Shampoo, Nourishing Conditioner, Firming Body Nourisher, Energizing Shower Gel, and Intensive Hand Therapy.

All Other

In addition to these principal product lines, we have developed and sell to Associates materials and online tools designed to assist them in building their businesses and selling our products. These resource materials or sales tools include product brochures and business forms that are designed by us and printed by outside publishers. We periodically contract with authors and publishers to produce or provide books, tapes, and other items that deal with health topics and personal motivation, which we then sell to Associates. We also write and develop our own materials for CDs and DVDs, which are produced by our wholly-owned subsidiary FMG Productions. New Associates are required to purchase a starter kit, which contains USANA training materials that assist Associates in starting and growing their businesses. Associates do not earn commissions on the sale of starter kits or sales tools.

The following table summarizes the approximate percentage of total product revenue for the Direct Selling segment contributed by major product line for the six months ended as of the dates indicated:

Product Line	Sales By Product Line Six Months Ended	
	July 2, 2005	July 1, 2006
USANA ^â Nutritionals		
Essentials *	37%	38%
Optimizers	35%	33%
Macro Optimizers	9%	14%
Sensé — beautiful science ^â	15%	12%
All Other	4%	3%

* The Essentials category under the USANA^â Nutritionals product line includes USANA^â Essentials, HealthPak 100^Ô, Body Rox^Ô, and Usanimals^Ô.

Key Products

The following highlights sales data for our top-selling products as a percentage of Direct Selling segment product sales for the

six months ended as of the dates indicated.

	<u>Six Months Ended</u>	
	<u>July 2,</u> <u>2005</u>	<u>July 1,</u> <u>2006</u>
USANA [®] Essentials	22%	22%
HealthPak 100™	12%	14%
Proflavano [®]	10%	9%

Forward-Looking Statements and Certain Risks

The statements contained in this report that are not purely historical are considered to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act. These statements represent our expectations, hopes, beliefs, anticipations, commitments, intentions, and strategies regarding the future. They may be identified by the use of words or phrases such as “believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” and “potential,” among others. Forward-looking statements include, but are not limited to, statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue, and expense levels in the future and the sufficiency of our existing assets to fund future operations and capital spending needs. Readers are cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed in these forward-looking statements for the reasons detailed in our most recent Annual Report on Form 10-K at pages 20 through 30. The fact that some of the risk factors may be the same or similar to our past reports filed with the Securities and Exchange Commission means only that the risks are present in multiple periods. We believe that many of the risks detailed here and in our other SEC filings are part of doing business in the industry in which we operate and compete and will likely be present in all periods reported. The fact that certain risks are endemic to the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

- Our ability to attract and maintain a sufficient number of Associates;
- High turnover of Associates;
- Our dependence upon a network marketing system to distribute our products;
- Activities of our independent Associates;
- Our planned expansion into international markets, including delays in commencement of sales in any new market, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;
- Rigorous government scrutiny of network marketing practices;
- Potential political events that may negatively affect economic conditions;
- Potential natural disasters that may negatively affect economic conditions;
- Potential effects of adverse publicity regarding nutritional supplements or the network marketing industry;
- Reliance on key management personnel, including our Founder, Chairman of the Board of Directors, and Chief Executive Officer Myron W. Wentz, Ph.D.;
- Extensive government regulation of the Company’s products, manufacturing, and network marketing system;
- Potential inability to sustain or manage growth, including the failure to continue to develop new products;
- An increase in the amount of Associate incentives paid;
- Our reliance on the use of information technology;
- The adverse effect of the loss of a high-level sponsoring Associate, together with a group of leading Associates, in that person’s downline;
- The loss of market share of our products or the Associates to competitors;

- Potential adverse effects of taxation and transfer pricing regulations;
- The fluctuation in the value of foreign currencies against the US dollar;
- Our reliance on outside suppliers for raw materials;
- Shortages of raw materials that we use in certain of our products;
- Significant price increases of our key raw materials;
- Product liability claims and other risks associated with our manufacturing activity;
- Intellectual property risks;
- Liability claims associated with our “Athlete Guarantee” program; and
- Disruptions to shipping channels that are used to distribute our products to international warehouses.

Results of Operations

Implementation of SFAS No. 123(R)

Effective January 1, 2006, the Company adopted the provisions of SFAS No. 123(R), which require equity-based compensation expense to be recognized in financial statements. The Company used the modified version of prospective application to adopt these provisions. Under this method, compensation expense includes the estimated fair value of equity awards vested during the reported period. Our financial statements for 2006 interim periods are the first to reflect equity-based compensation expense. Equity-based compensation expense recognized for the quarter, and six months ended July 1, 2006 was comprised as follows:

	<u>Quarter Ended July 1, 2006</u>	<u>Six Months Ended July 1, 2006</u>
Cost of sales	\$ 143	\$ 270
Selling, general and administrative	930	1,637
Research and development	132	245
	<u>\$ 1,205</u>	<u>\$ 2,152</u>

Net of tax, earnings for the quarter and six months ended July 1, 2006 were reduced by \$819 thousand, and \$1,504 thousand, respectively. Earnings per basic and diluted share were reduced \$0.04, and \$0.07, respectively, from what earnings would have been exclusive of equity-based compensation. The Company currently estimates that equity-based compensation expense will reduce basic and diluted earnings per share in 2006 by \$0.18. The following table shows remaining unrecognized compensation expense on a pre-tax basis related to all types of nonvested equity awards outstanding as of July 1, 2006. This table does not include an estimate for future grants that may be issued.

Remainder of 2006	\$ 2,578
2007	5,095
2008	4,718
2009	2,840
2010	2,203
Thereafter	412
	<u>\$17,846</u>

The expense above is expected to be recognized over a weighted-average period of 2.4 years.

Quarters Ended July 2, 2005 and July 1, 2006

Net Sales. Net sales increased 14.5% to \$93.9 million for the quarter ended July 1, 2006, an increase of \$11.9 million from \$82.0 million for the comparable quarter in 2005. During the current quarter, net sales in the Direct Selling segment increased by \$11.3 million, and net sales in the Contract Manufacturing segment increased by \$0.6 million, when compared with the same period in 2005.

The following table summarizes the changes in net sales by segment and country for the fiscal quarters ended July 2, 2005 and July 1, 2006.

Segment / Region	Sales By Segment and Region (in thousands) Quarter Ended				Change from Prior Year	Percent Change
	July 2, 2005		July 1, 2006			
Direct Selling						
North America						
United States	\$ 33,067	40.3%	\$ 39,818	42.4%	\$ 6,751	20.4%
Canada	15,287	18.6%	18,010	19.2%	2,723	17.8%
Mexico	3,910	4.8%	4,373	4.6%	463	11.8%
North America Total	52,264	63.7%	62,201	66.2%	9,937	19.0%
Pacific Rim						
Australia-New Zealand	11,241	13.7%	12,291	13.1%	1,050	9.3%
Hong Kong	3,377	4.1%	3,480	3.7%	103	3.1%
Japan	2,620	3.2%	2,417	2.6%	(203)	(7.7%)
Taiwan	5,381	6.6%	5,034	5.4%	(347)	(6.4%)
South Korea	1,323	1.6%	1,762	1.9%	439	33.2%
Singapore	3,606	4.4%	3,892	4.1%	286	7.9%
Pacific Rim Total	27,548	33.6%	28,876	30.8%	1,328	4.8%
Segment Total	79,812	97.3%	91,077	97.0%	11,265	14.1%
Contract Manufacturing	2,203	2.7%	2,834	3.0%	631	28.6%
Consolidated	\$ 82,015	100.0%	\$ 93,911	100.0%	\$ 11,896	14.5%

The increase in net sales from the Direct Selling segment in North America was 19.0% compared with the second quarter of 2005. On a constant currency basis, sales in this region improved 15.8% over the same period of the prior year. The growth in this region was largely driven by strong sales in the United States, the Company's largest and most mature market, and Canada. Mexico also contributed to the increase in this region by growing 11.8% over the same period of the prior year. The overall sales increase in this region during the second quarter was driven by a 16.9% increase in the number of active Associates.

Net sales in the Pacific Rim region of the Direct Selling segment improved 4.8% over the second quarter of 2005. This increase came primarily from the Australia-New Zealand and South Korea markets. On a constant currency basis, sales in this region improved 7.7% over the same period of the prior year. The overall sales increase in this region during the second quarter was driven by an 8.3% increase in the number of active Associates, compared with the same period of the prior year.

The increase in net sales from our Contract Manufacturing segment can be attributed primarily to the fulfillment of backlogged orders. We now believe that the backlogged orders are essentially fulfilled and anticipate that sales from this segment will be between \$1.5 million and \$2.0 million per quarter for the foreseeable future.

By way of guidance, typically our sequential sales growth is soft in the third quarter due to the slowdown that happens prior to our International Convention, which is held in mid-September. Based on information that is currently available to the Company, we expect consolidated net sales between \$94 and \$96 million for the third quarter of 2006. We have removed from our fiscal year 2006 guidance the expectation of opening a new market due to the difficulty in obtaining a business license and the lack of transparency to the approval process in that market. We now expect consolidated net sales to grow between 15% and 17% for the fiscal year. For the near future, our primary focus will be to obtain growth from existing markets in the Direct Selling segment.

The following tables summarize the growth in active customers for the Direct Selling segment by geographic region and country as of the dates indicated:

Active Associates By Region
(rounded to the nearest thousand)

Region	As of July 2, 2005		As of July 1, 2006		Change from Prior Year	Percent Change
North America						
United States	46,000	36.8%	57,000	40.1%	11,000	23.9%
Canada	22,000	17.6%	23,000	16.2%	1,000	4.5%
Mexico	9,000	7.2%	10,000	7.1%	1,000	11.1%
North America Total	77,000	61.6%	90,000	63.4%	13,000	16.9%
Pacific Rim						
Australia-New Zealand	16,000	12.8%	18,000	12.7%	2,000	12.5%
Hong Kong	5,000	4.0%	6,000	4.2%	1,000	20.0%
Japan	4,000	3.2%	4,000	2.8%	—	0.0%
Taiwan	12,000	9.6%	13,000	9.2%	1,000	8.3%
South Korea	2,000	1.6%	2,000	1.4%	—	0.0%
Singapore	9,000	7.2%	9,000	6.3%	—	0.0%
Pacific Rim Total	48,000	38.4%	52,000	36.6%	4,000	8.3%
Total	125,000	100.0%	142,000	100.0%	17,000	13.6%

We believe that the year-over-year second quarter increase in the number of active Associates was primarily due to ongoing communication with Associate leaders in the field as well as company-sponsored events and promotions held to motivate Associates.

Active Preferred Customers By Region
(rounded to the nearest thousand)

Region	As of July 2, 2005		As of July 2, 2006		Change from Prior Year	Percent Change
North America						
United States	41,000	62.1%	48,000	64.0%	7,000	17.1%
Canada	18,000	27.3%	18,000	24.0%	—	0.0%
Mexico	1,000	1.5%	2,000	2.7%	1,000	100.0%
North America Total	60,000	90.9%	68,000	90.7%	8,000	13.3%
Pacific Rim						
Australia-New Zealand	5,000	7.6%	6,000	8.0%	1,000	20.0%
Hong Kong	**	0.0%	**	0.0%	—	N/A
Japan	1,000	1.5%	1,000	1.3%	—	0.0%
Taiwan	**	0.0%	**	0.0%	—	N/A
South Korea	**	0.0%	**	0.0%	—	N/A
Singapore	**	0.0%	**	0.0%	—	N/A
Pacific Rim Total	6,000	9.1%	7,000	9.3%	1,000	16.7%
Total	66,000	100.0%	75,000	100.0%	9,000	13.6%

**Active Preferred Customer count is less than 500.

Total Active Customers By Region
(rounded to the nearest thousand)

Region	As of July 2, 2005		As of July 1, 2006		Change from Prior Year	Percent Change
North America						
United States	87,000	45.5%	105,000	48.4%	18,000	20.7%
Canada	40,000	20.9%	41,000	18.9%	1,000	2.5%
Mexico	10,000	5.3%	12,000	5.5%	2,000	20.0%
North America Total	137,000	71.7%	158,000	72.8%	21,000	15.3%
Pacific Rim						
Australia-New Zealand	21,000	11.0%	24,000	11.1%	3,000	14.3%
Hong Kong	5,000	2.6%	6,000	2.8%	1,000	20.0%

Japan	5,000	2.6%	5,000	2.3%	—	0.0%
Taiwan	12,000	6.3%	13,000	6.0%	1,000	8.3%
South Korea	2,000	1.1%	2,000	0.9%	—	0.0%
Singapore	9,000	4.7%	9,000	4.1%	—	0.0%
Pacific Rim Total	<u>54,000</u>	<u>28.3%</u>	<u>59,000</u>	<u>27.2%</u>	<u>5,000</u>	<u>9.3%</u>
Total	<u>191,000</u>	<u>100.0%</u>	<u>217,000</u>	<u>100.0%</u>	<u>26,000</u>	<u>13.6%</u>

Gross Profit. Consolidated gross profit increased slightly to 76.3% of net sales for the quarter ended July 1, 2006, from 76.2% for the comparable quarter in 2005. This increase was generated by the Direct Selling segment, and was partially offset due to a larger percent of total net sales coming from the Contract Manufacturing segment, which yields meaningfully lower gross profit margins than the Direct Selling segment.

Gross profit in the Direct Selling segment for the quarter ended July 1, 2006 improved to 78.8% of net segment sales from 78.5% for the same quarter in 2005. The increase in gross profit margins contributed by the Direct Selling segment can be attributed mainly to lower costs on certain key raw materials such as Coenzyme Q10 and was partially offset by higher freight costs on shipments to customers.

The Contract Manufacturing segment generated minimal gross profit margins from its third-party customers in the second quarters of both 2006 and 2005. The absence of gross profit margin from third-party customers can be attributed, for the most part, to production inefficiencies in the segment's third-party business. In the second quarter of 2006, certain inventory was disposed of in this segment as a result of the Company continuing to focus more on its Direct Selling segment business. Absent the impact of disposing of the inventory noted above, gross profit margin in the Contract Manufacturing segment would have approached 12% for the second quarter of 2006. We note, however, that the Contract Manufacturing business was acquired primarily as a means to produce the Company's Sense™ product line and not necessarily for the third-party business.

We believe that our consolidated gross profit margin will improve modestly in the third quarter of 2006 from current levels due to the following:

- The Contract Manufacturing segment will continue to represent a smaller percentage of consolidated net sales;
- Relatively lower costs on certain key raw materials in the Direct Selling segment; and
- Increased production efficiencies in the Contract Manufacturing segment.

Associate Incentives. Expenses related to Associate incentives are incurred only by the Direct Selling segment and represent the most significant cost as a percentage of net sales for this segment. Associate incentives increased to 41.1% of net segment sales during the second quarter of 2006, compared to 40.0% for the same period in the prior year. The increase in Associate incentives, relative to net segment sales, can be attributed to an increase in the amounts that we paid on contests and promotions during the current quarter. We believe that Associate incentives will continue to be approximately 41% of net segment sales for the foreseeable future. As we look for ways to increase sales through Associate activity, our Associate incentives as a percent of net segment sales may fluctuate modestly.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased to 19.2% of net sales for the quarter ended July 1, 2006 from 18.5% for the comparable quarter in 2005. The increase, as a percentage of net sales, can be attributed to the recognition of equity-based compensation expense totaling \$930 thousand as a result of the adoption of SFAS No. 123(R) (equity-based compensation expense was not recognized in prior years' income statements), offset partially by leverage generated on an increasing sales base.

In absolute terms, our selling, general and administrative expenses increased by \$2.8 million for the quarter ended July 1, 2006, when compared with the second quarter of 2005. This absolute increase in selling, general and administrative expenses can be primarily attributed to increased spending in many of our markets to support growing sales, an increasing number of Associates, and the inclusion of equity-based compensation as noted above.

We believe that selling, general and administrative expenses, as a percentage of net sales, in the third quarter of 2006 will be slightly lower than the second quarter of 2006.

Other Income (Expense). Other income (expense) changed from net other expense of \$67 thousand in the second quarter of 2005, to net other income of \$336 thousand for the quarter ended July 1, 2006. This change in net other income (expense) of \$403 thousand can primarily be attributed to foreign currency gains of approximately \$174 thousand in the second quarter of 2006, compared to foreign currency losses of approximately \$156 thousand in the second quarter of 2005, and, to a lesser extent, an increase in interest income.

Income taxes. The Company's year-to-date effective tax rate was adjusted from 35.5% to 34.8%, primarily due to better-than-expected results from Extraterritorial Income Exclusion and the Qualified Production Activity deduction. This adjustment brought the rate for the quarter ended July 1, 2006 to 34.1%, which contributed \$0.01 to diluted earnings per share for the quarter.

Net Earnings. Net earnings increased 8.4% to \$10.3 million for the quarter ended July 1, 2006, an increase of \$801 thousand, from \$9.5 million for the comparable quarter in 2005. The increase in net earnings can be mostly attributed to increased net sales.

Diluted earnings per share improved to \$0.55 for the second quarter of 2006, an increase of 14.6% from the \$0.48 reported for the comparable quarter in 2005. Diluted earnings per share included equity-based compensation expense that reduced

earnings per share by \$0.04 in the current quarter; whereas the diluted earnings per share of \$0.48 in the prior year quarter did not include any impact from equity-based compensation expense. We expect diluted earnings per share in the third quarter of 2006 to be between \$0.55 and \$0.57, which includes an estimated reduction due to equity-based compensation expense of \$0.05 per share. We expect diluted earnings per share for fiscal year 2006 to grow between 17% and 20%, excluding equity-based compensation expense. Both third quarter and fiscal year 2006 guidance assume a tax rate for 2006 of 34.8%. We also anticipate that equity-based compensation expense will reduce 2006 diluted earnings per share by approximately \$0.18.

Six Months Ended July 2, 2005 and July 1, 2006

Net Sales. Consolidated net sales increased 15.7% to \$183.6 million for the six months ended July 1, 2006, an increase of \$25 million from \$158.6 million for the comparable period in 2005. The change consisted of a \$23.4 million increase in the Direct Selling segment, and a \$1.6 million increase in the Contract Manufacturing segment.

The following table summarizes the changes in net sales by segment and country for the six months ended July 2, 2005 and July 1, 2006.

Segment / Region	Sales By Segment and Region (in thousands)				Change from Prior Year	Percent Change
	Six Months Ended					
	July 2, 2005		July 1, 2006			
Direct Selling						
North America						
United States	\$ 64,270	40.5%	\$ 78,875	43.0%	\$ 14,605	22.7%
Canada	30,149	19.0%	34,989	19.1%	4,840	16.1%
Mexico	7,103	4.5%	8,471	4.6%	1,368	19.3%
North America Total	101,522	64.0%	122,335	66.7%	20,813	20.5%
Pacific Rim						
Australia-New Zealand	21,885	13.8%	23,565	12.9%	1,680	7.7%
Hong Kong	6,417	4.1%	6,656	3.6%	239	3.7%
Japan	5,118	3.2%	4,849	2.6%	(269)	(5.3%)
Taiwan	10,445	6.6%	10,015	5.5%	(430)	(4.1%)
South Korea	2,368	1.5%	2,978	1.6%	610	25.8%
Singapore	6,706	4.2%	7,432	4.0%	726	10.8%
Pacific Rim Total	52,939	33.4%	55,495	30.2%	2,556	4.8%
Segment Total	154,461	97.4%	177,830	96.9%	23,369	15.1%
Contract Manufacturing	4,132	2.6%	5,732	3.1%	1,600	38.7%
Consolidated	\$ 158,593	100.0%	\$ 183,562	100.0%	\$ 24,969	15.7%

The increase in net sales from the Direct Selling segment in North America was 20.5% compared with the first six months of 2005, and was the result of strong growth in all three countries within this region. On a constant currency basis, sales in this region improved 17.7% over the same period of the prior year. The overall sales increase in this region during the first six months of 2006 was driven largely by an increase in the number of active Associates.

Net sales in the Pacific Rim region of the Direct Selling segment improved 4.8% over the first six months of 2005. This increase came primarily from Australia-New Zealand, South Korea, and Singapore. On a constant currency basis, sales in this region increased 8.2% over the same period of the prior year. The overall sales increase in this region during the first six months of 2006 was also driven largely by an increase in the number of active Associates.

The increase in net sales of our Contract Manufacturing segment can be attributed mostly to the fulfillment of backlogged orders.

Gross Profit. Consolidated gross profit decreased slightly to 76.2% of net sales for the six months ended July 1, 2006, from 76.3% for the comparable period in 2005. The decline in gross profit margins can be attributed to a larger percent of total net sales coming from the Contract Manufacturing segment, which yields meaningfully lower gross profit margins than the Direct Selling segment, and to a lesser extent, the expensing of equity-based compensation, which increased cost of sales by \$270 thousand for the first six months of 2006.

The Direct Selling segment's gross profit margin improved to 78.8% during the first six months of 2006, compared to 78.4% for the six months ended July 2, 2005. The improvement in gross profit margin for the Direct Selling segment can mainly be attributed to lower costs on certain key raw materials such as Coenzyme Q10, partially offset by higher freight costs on shipments to customers.

The Contract Manufacturing segment generated minimal gross profit margins from its third-party customers during the six months ended July 1, 2006, compared to a gross profit margin of 0.5% during the comparable period of the prior year. The absence of gross profit margin from third-party customers can be attributed to production inefficiencies in the segment's third-party business. In the second quarter of 2006, certain inventory was disposed of in this segment as a result of the Company continuing to focus more on its Direct Selling segment business. Absent the impact of disposing of the inventory noted above, gross profit margin in the Contract Manufacturing segment would have been approximately 6% for the first six months of 2006. We note, however, that the Contract Manufacturing business was acquired primarily as a means to produce the Company's Sensé™ product line, not for the third-party business.

Associate Incentives. Associate incentives increased to 41.0% of net segment sales for the six months ended July 1, 2006, compared to 39.8% in the comparable period of 2005. The increase in Associate incentives, relative to net segment sales, can be attributed to an increase in the amounts that we paid on contests and promotions during the first six months of 2006, as well as a higher proportion of commissionable sales.

Selling, General and Administrative Expenses. Selling, general and administrative expense increased to 19.4% of net sales for the six months ended July 1, 2006, from 18.9% for the comparable period in 2005. The increase, as a percentage of net sales, can be attributed largely to the recognition of equity-based compensation expense totaling \$1.6 million as a result of the adoption of SFAS No. 123(R) (equity-based compensation expense was not recognized in prior years' income statements), and, to our inaugural Asia-Pacific convention, which added \$524 thousand to our selling, general and administrative expenses. The increased cost as a percentage of sales resulting from the aforementioned expenses was partially offset by leverage generated on an increasing sales base.

In absolute terms, selling, general and administrative expenses increased by \$5.6 million for the six months ended July 1, 2006, when compared to the same period of the prior year. This absolute increase in selling, general and administrative expenses can be attributed, for the most part, to the following:

- An increase in spending in many of our markets to support growing sales and an increasing number of Associates;
- Expensing of equity-based compensation during the first six months of 2006, as noted above; and
- Costs associated with our inaugural Asia-Pacific convention that we held in March 2006.

Other Income. Other income increased \$533 thousand from \$98 thousand during the first six months of 2005, to \$631 thousand during the first six months of 2006. This change in net other income can primarily be attributed to foreign currency gains of approximately \$322 thousand during the first six months of 2006, compared to foreign currency losses of approximately \$96 thousand in the comparable period of the prior year, and, to a lesser extent, an increase in interest income.

Income Taxes. Income taxes totaled 34.8% of earnings before income taxes for the first six months of 2006, compared with 35.0% for the first six months of 2005. The decrease in the effective tax rate was mostly attributed to reduced foreign tax rates and better-than-expected results from Extraterritorial Income Exclusion and the Qualified Production Activity deduction. In 2007, the Qualified Production Activity deduction will increase to 6% when the full repeal of the Extraterritorial Income Exclusion takes place.

We expect the effective tax rate for the full year of 2006 to be approximately 34.8%. This is an increase of 1.1% from the 2005 effective tax rate of 33.7% due primarily to reduced benefits from the Extraterritorial Income Exclusion. The effective tax rate for the last six months of 2006 can be affected by the type and amount of stock options exercised during the period, among other things.

Net Earnings. Net earnings increased 7.8% to \$19.9 million for the six months ended July 1, 2006, an increase of \$1.4 million from \$18.5 million for the comparable period in 2005. The increase in net earnings can be mainly attributed to higher net sales.

Diluted earnings per share improved to \$1.05 for the first six months of 2006, an increase of \$0.12, or 12.9%, from the \$0.93 reported for the comparable period in 2005. The diluted earnings per share of \$1.05 included equity-based compensation expense that reduced earnings per share by \$0.07 in the first six months of 2006; whereas the diluted earnings per share of \$0.93 during the comparable period of the prior year did not include any impact from equity-based compensation expense.

Liquidity and Capital Resources

We continue to finance our growth with cash flows from operations. During the first six months of 2006, net cash flows from operating activities totaled \$30.2 million, compared to \$22.0 million for the same period in 2006. Cash and cash equivalents decreased to \$9.2 million at July 1, 2006, from \$10.6 million at December 31, 2005, and \$25.5 million at April 1, 2006. Additionally, net working capital decreased to \$7.4 million at July 1, 2006, compared to net working capital of \$15.3 million at December 31, 2005. The decrease in cash and cash equivalents and net working capital during the first six months of 2006 can be primarily attributed to the purchase of shares under the Company's Share Repurchase Plan totaling \$30.1 million.

The Company has continued to grow significantly over the last several years and requires additional administrative and warehouse space, as well as additional parking space. To address this need, the Company is expanding its corporate headquarters and anticipates the facility expansion will require an investment between \$8 million and \$10 million during 2006. As of July 1, 2006, investments in this project totaled approximately \$867 thousand. The total estimated investment to complete this project is about \$13 million.

During the quarter ended July 1, 2006, our \$10 million credit facility was amended, increasing our line of credit to \$25 million. Also affected by the amendment were the restrictive covenants, which are now based on EBITDA and a debt coverage ratio. As of July 1, 2006, we were in compliance with these covenants.

We believe that current cash balances, cash provided by operations, and amounts available under the line of credit will be sufficient to cover our capital needs in the ordinary course of business for the foreseeable future. If we experience an adverse operating environment or unusual capital expenditure requirements, additional financing may be required. However, no assurance can be given that additional financing, if required, would be available on favorable terms. We might also require or seek additional financing for the purpose of expanding new markets, growing our existing markets, and for other reasons. Such financing may include the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments convertible into equity securities could result in immediate and possibly significant dilution to existing shareholders.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We conduct our business in several countries and intend to continue to expand our foreign operations. Net sales, earnings from operations, and net earnings are affected by fluctuations in currency exchange rates, interest rates, and other uncertainties inherent in doing business and selling product in more than one currency. In addition, our operations are exposed to risks associated with changes in social, political, and economic conditions inherent in foreign operations, including changes in the laws and policies that govern foreign investment in countries where we have operations, as well as, to a lesser extent, changes in United States laws and regulations relating to foreign trade and investment.

Foreign Currency Risks. Consolidated net sales outside the United States represented 56.9% and 53.9% of net sales for the six months ended July 2, 2005 and July 1, 2006, respectively. Inventory purchases are transacted primarily in U.S. dollars from

vendors located in the United States. The local currency of each international subsidiary is considered the functional currency, with all revenue and expenses translated at weighted average exchange rates for reported periods. In general, our reported sales and earnings are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. Changes in currency exchange rates affect the relative prices at which we sell our products. Given the uncertainty of exchange rate fluctuations, we cannot estimate the effect of these fluctuations on our future business, product pricing, results of operations, or financial condition.

We seek to reduce exposure to fluctuations in foreign exchange rates by creating offsetting positions through the use of foreign currency exchange contracts. We do not use derivative financial instruments for trading or speculative purposes. Our strategy in this regard includes entering into foreign currency exchange contracts to manage currency fluctuations in our expected net cash flow from certain of our international markets, which are primarily represented by intercompany cash transfers. As of July 1, 2006, option contracts were in place to offset our exposure to the Canadian Dollar, Australian Dollar, New Zealand Dollar, and Mexican Peso.

Following are the average exchange rates of foreign currency units to one U.S. dollar for each of our foreign markets for the periods ended as of the dates indicated:

	<u>Quarter Ended</u>		<u>Six Months Ended</u>	
	<u>July 2, 2005</u>	<u>July 1, 2006</u>	<u>July 2, 2005</u>	<u>July 1, 2006</u>
Canadian Dollar	1.24	1.12	1.23	1.14
Australian Dollar	1.30	1.34	1.29	1.35
New Zealand Dollar	1.40	1.60	1.40	1.55
Hong Kong Dollar	7.79	7.76	7.79	7.76
Japanese Yen	107.59	114.29	106.06	115.57
New Taiwan Dollar	31.39	32.17	31.43	32.24
Korean Won	1,008.72	949.37	1,015.54	962.55
Singapore Dollar	1.66	1.59	1.65	1.61

Mexican Peso	10.95	11.18	11.07	10.89
Chinese Yuan	*	8.01	*	8.03

* Company did not have operations in market during period indicated.

Interest Rate Risks. As of July 1, 2006, we had no outstanding debt and, therefore, we currently have no direct exposure to interest rate risk. It may become necessary to borrow in the future in order to meet our financing needs, as circumstances require. In the event that it becomes necessary to finance with debt, there can be no assurance that we will be able to borrow at favorable rates.

Item 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended). Based on the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

30

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended July 1, 2006 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1A. RISK FACTORS

We attempt to identify, manage and mitigate the risks and uncertainties associated with our business to the extent practical. However, some level of risk and uncertainty will always be present. Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2005 describes some of the risks and uncertainties associated with our business. These risks and uncertainties have the potential to materially affect our business, financial condition, results of operations, cash flows, projected results and future prospects. We have revised the following risk factor which was previously disclosed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2005:

Network marketing is subject to intense government scrutiny and regulation, which adds to the expense of doing business and the possibility that changes in the law might adversely affect our ability to sell some of our products in certain markets. Network marketing systems such as ours are frequently subject to laws and regulations, including laws and regulations directed at ensuring that product sales are made to consumers of the products and that compensation, recognition, and advancement within the marketing organization are based on the sale of products rather than investment in the sponsoring company. We are subject to the risk that, in one or more of our present or future markets, our marketing system could be found not to comply with these laws and regulations or may be prohibited. Failure to comply with these laws and regulations or such a prohibition could have a material adverse effect on our business, financial condition, and results of operations. Further we may simply be prohibited from distributing products through a network-marketing channel in some foreign countries, or be forced to alter our Compensation Plan.

We are also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, which could require us to change or modify the way we conduct business in certain markets. The United States Federal Trade Commission released a proposed New Business Opportunity Rule on April 5, 2006. The proposed rule would require pre-sale disclosures for all business opportunities, which might include network marketing compensation plans. The New Business Opportunity Rule is currently only a proposed rule. If implemented at all, the rule ultimately may not be implemented in a form that applies to network marketing compensation plans, or may change significantly before it is implemented. If the proposed rule were adopted as currently proposed, it might require USANA to change some of its current practices regarding pre-sale disclosures.

31

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases made for each fiscal month during the quarter ended July 1, 2006 are summarized in the following table:

Issuer Purchases of Equity Securities
(amounts in thousands, except per share data)

<u>Period</u>	<u>Total Number of Shares Purchased</u>	<u>Average Price Paid per Share</u>	<u>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</u>	<u>Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs</u>
April 2, 2006 through May 6, 2006 (Fiscal April)	173	\$ 37.58	173	\$ 34,299
May 7, 2006 through June 3, 2006 (Fiscal May)	470	\$ 37.72	470	\$ 16,570
June 4, 2006 through July 1, 2006 (Fiscal June)	158	\$ 37.45	158	\$ 10,654
	<u>801</u>	<u>\$ 37.64</u>	<u>801</u>	

Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At our Annual Meeting of Shareholders on April 19, 2006, the following actions were submitted and approved by vote of the shareholders:

- (1) Election of five directors,
- (2) Ratification of the Board's selection of Grant Thornton LLP as our independent certified public accountants of USANA for fiscal year 2006,
- (3) The USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan,
- (4) An amendment to the Company's Articles of Incorporation to include a provision limiting the liability of directors to the Company for monetary damage, and
- (5) An amendment to the Company's Articles of Incorporation to include a provision indemnifying the Company's officers and directors against expenses and costs incurred by such persons in connection with certain legal proceedings.

32

A total of 16,959,060 shares (approximately 92%) of the issued and outstanding shares of USANA were represented by proxy or in person at the meeting. These shares were voted on the matters described above as follows:

1. For the directors as follows:

<u>Name</u>	<u>Number of Shares For</u>	<u>Number of Shares Abstaining/Withheld</u>
Myron W. Wentz, PhD	16,770,742	188,318
Ronald S. Poelman	16,608,475	350,585
Robert Anciaux	16,684,734	274,326
Denis E. Waitley, PhD	16,743,179	215,881
Jerry G. McClain	16,643,542	315,518

2. For the ratification of the Board's selection of Grant Thornton LLP as the independent certified public accountants of USANA for fiscal year 2006 as follows:

<u>Number of Shares For</u>	<u>Number of Shares Against</u>	<u>Number of Shares Abstaining/Withheld</u>
16,854,094	85,595	19,370

3. For the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan as follows:

<u>Number of Shares For</u>	<u>Number of Shares Against</u>	<u>Number of Shares Abstaining/Withheld</u>	<u>Broker Non-votes</u>
10,643,400	2,792,226	21,624	3,501,810

4. For an amendment to the Company's Articles of Incorporation to include a provision limiting the liability of directors to the Company for monetary damages as follows:

<u>Number of Shares For</u>	<u>Number of Shares Against</u>	<u>Number of Shares Abstaining/Withheld</u>
16,734,109	157,988	66,963

5. For an amendment to the Company's Articles of Incorporation to include a provision indemnifying the Company's officers and directors against expenses and costs incurred by such persons in connection with certain legal proceedings as follows:

<u>Number of Shares For</u>	<u>Number of Shares Against</u>	<u>Number of Shares Abstaining/Withheld</u>
16,785,304	102,140	71,616

Item 6. EXHIBITS

<u>Exhibit Number</u>	<u>Description</u>
3.1	Amended and Restated Articles of Incorporation [Incorporated by reference to Report on Form 8-K, filed April 25, 2006]
3.2	Bylaws [Incorporated by reference to Report on Form 8-K, filed April 25, 2006]
4.1	Specimen Stock Certificate for Common Stock, no par value [Incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993]
10.1	2002 USANA Health Sciences, Inc. Stock Option Plan [Incorporated by reference to Registration Statement on Form S-8, filed July 18, 2002]
10.2	Credit Agreement by and between Bank of America, N.A. and USANA Health Sciences, Inc. [Incorporated by reference to Report on Form 10-Q for the period ended July 3, 2004]
10.3	Amendment dated May 17, 2006 to Credit Agreement dated June 16, 2004 (filed herewith)
10.4	USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan [Incorporated by reference to Report on Form 8-K, filed April 25, 2006]
10.5	Form of Stock Option Agreement for award of non-statutory stock options to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan [Incorporated by reference to Report on Form 8-K, filed April 26, 2006]
10.6	Form of Stock Option Agreement for award of non-statutory stock options to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan [Incorporated by reference to Report on Form 8-K, filed April 26, 2006]
10.7	Form of Incentive Stock Option Agreement under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan [Incorporated by reference to Report on Form 8-K, filed April 26, 2006]
10.8	Form of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan [Incorporated by reference to Report on Form 8-K, filed April 26, 2006]
10.9	Form of Stock-Settled Stock Appreciation Rights Award Agreement for directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan [Incorporated by reference to Report on Form 8-K, filed April 26, 2006]
10.10	Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan [Incorporated by reference to Report on Form 8-K, filed April 26, 2006]
11.1	Computation of Net Income per Share (included in Notes to Consolidated Financial Statements)

- 31.1 Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
- 32.2 Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

USANA HEALTH SCIENCES, INC.

Date: August 8, 2006

/s/ Gilbert A. Fuller
Gilbert A. Fuller
Chief Financial Officer
(Principal Financial and Accounting Officer)

AMENDMENT TO CREDIT AGREEMENT

This AMENDMENT TO CREDIT AGREEMENT ("Amendment") is entered into as of May 17, 2006, by USANA HEALTH SCIENCES, INC., a Utah corporation (together with its successors, "Borrower"), and BANK OF AMERICA, N.A., a national banking association (together with its successors and assigns, "Bank").

RECITALS

- A. Borrower and Bank are parties to that certain Credit Agreement dated as of June 16, 2004, as amended by that certain Waiver and Amendment to Credit Agreement dated as of February 2, 2006 (as the same may be amended, modified or extended from time to time the "Credit Agreement") and the related Loan Documents described therein.
- B. Pursuant to the terms of the Credit Agreement, Bank has made and does make available to Borrower a revolving line of credit in the amount of \$10,000,000, which revolving line of credit terminates on May 30, 2006.
- C. Borrower has requested that Bank increase the amount of the revolving line of credit to \$25,000,000, extend its termination to May 30, 2011 and to make certain other modifications to the Credit Agreement, which Bank has agreed to do on the terms and conditions set forth in this Amendment.

NOW, THEREFORE, in consideration of the foregoing, the mutual covenants and agreements herein contained, and for other good and valuable consideration receipt of which is hereby acknowledged, Borrower and Bank hereby agree as follows:

1. Definitions; Interpretation. All capitalized terms used in this Amendment and not otherwise defined herein have the meanings specified in the Credit Agreement. The rules of construction and interpretation specified in Sections 1.02 and 1.05 of the Credit Agreement also apply to this Amendment and are incorporated herein by this reference.

2. Amendments to Credit Agreement. The Credit Agreement is amended as follows:

(a) Amendment to Definitions. In Section 1.01, amendments are made to the definitions, as follows:

(i) Applicable Rate. The definition of "Applicable Rate" is amended and restated to read as follows:

"Applicable Rate" means, from time to time, the following percentages per annum (a) in respect of the Commitment fee, 0.20%, (b) in respect of Eurodollar Rate Loans, the Eurodollar Rate plus 1.00%, (c) in respect of Base Rate Loans, the Base Rate minus 0.50% and (d) in respect of the Letter of Credit fee for standby Letters of Credit, 1.00%.

(ii) Commitment. The definition of "Commitment" is amended and restated to read as follows:

"Commitment" means the obligation of Bank to make Loans and L/C Credit Extensions hereunder in an aggregate principal amount at any one time not to exceed \$25,000,000, as such amount may be adjusted from time to time in accordance with this Agreement.

(iii) Consolidated Funded Debt. The definition of "Consolidated Funded Debt" is added to read as follows:

"Consolidated Funded Debt" means, as of any date of determination, for Borrower and its Subsidiaries on a consolidated basis, the sum of (a) the outstanding principal amount of all obligations, whether current or long-term, for borrowed money (including Obligations hereunder) and all obligations evidenced by bonds, debentures, notes, loan agreements or other similar instruments, plus (b) all purchase money Indebtedness, plus (c) all direct obligations arising under letters of credit (including standby and commercial), bankers' acceptances, bank guaranties, surety bonds and similar instruments, plus (d) all obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business), plus (e) Attributable Indebtedness in respect of capital leases and Synthetic Lease Obligations, plus (f) without duplication, all Guarantees with respect to outstanding Indebtedness of the types specified in clauses (a) through (e) above of Persons other than Borrower or any Subsidiary, plus (g) all Indebtedness of the types referred to in clauses (a) through (f) above of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which Borrower or a Subsidiary is a general partner or joint venturer, unless such Indebtedness is expressly made non-recourse to Borrower or such Subsidiary, minus (h) the aggregate amount of Subordinated Liabilities properly classified on such date as long term debt in accordance with GAAP.

(iv) Consolidated Funded Debt to EBITDA Ratio. The definition of "Funded Debt to EBITDA Ratio" is added to read as follows:

"Consolidated Funded Debt to EBITDA Ratio" means, as of any date of determination, the ratio of

(a) Consolidated Funded Debt as of such date to (b) Consolidated EBITDA for the period of the four prior fiscal quarters ending on such date.

(v) Consolidated Leverage Ratio. The definition of “Consolidated Leverage Ratio” is deleted.

(vi) Consolidated Tangible Net Worth. The definition of “Consolidated Tangible Net Worth” is deleted.

(vii) Consolidated Total Liabilities. The definition of “Consolidated Total Liabilities” is deleted.

(viii) Interest Payment Date. In the definition of “Interest Payment Date,” the phrase “provided, however, that if any Interest Period for a Eurodollar Rate Loan exceeds three months, the respective dates that fall every three months after the beginning of such Interest Period shall also be Interest Payment Dates;” is added at the end of clause (a).

(ix) Interest Period. In the definition of “Interest Period,” the phrase “one, two or three months” is amended and restated to read “one, two, three or six months.”

(x) Letter of Credit Sublimit. The definition of “Letter of Credit Sublimit” is amended and restated to read as follows:

“Letter of Credit Sublimit” means an amount equal to \$10,000,000. The Letter of Credit Sublimit is part of, and not in addition to, the Commitment.

(xi) Maturity Date. The definition of “Maturity Date” is amended and restated to read as follows:

“Maturity Date” means May 30, 2011.

(b) Addition of Section 2.11. Section 2.11 is hereby added to read as follows:

2.11 Increase in Commitment.

(a) Request for Increase. Provided there exists no Default, upon notice to Bank, Borrower may from time to time, request an increase in the Commitment by an amount (for all such requests) not exceeding \$15,000,000; provided that any such request for an increase shall be in a minimum amount of \$5,000,000 or a whole multiple of \$1,000,000 in excess thereof. At the time of sending such notice, Borrower shall specify the time period within which Bank is requested to respond (which shall in no event be less than ten Business Days from the date of delivery of such notice to Bank).

(b) Bank Election to Increase; Effective Date. Bank shall notify Borrower within such time period whether or not it agrees to increase the Commitment. In the event Bank does not respond within such time period, the Bank shall be deemed to have declined to increase the Commitment. If the Commitment is increased in accordance with this Section, Bank and Borrower shall determine the effective date (the “Increase Effective Date”).

(c) Conditions to Effectiveness of Increase. As a condition precedent to such increase, Borrower shall deliver to Bank a certificate of each Loan Party dated as of the Increase Effective Date signed by a Responsible Officer of such Loan Party (i) certifying and attaching the resolutions adopted by such Loan Party approving or consenting to such increase, and (ii) in the case of Borrower, certifying that, before and after giving effect to such increase, (A) the representations and warranties contained in Article V and the other Loan Documents are true and correct on and as of the Increase Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct as of such earlier date, and except that for purposes of this Section 2.11, the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01, and (B) no Default exists.

(c) Amendments to Section 6.12. Section 6.12 is hereby amended and restated to read as follows:

6.12 Financial Covenants.

(a) Maximum Funded Debt to EBITDA Ratio. Maintain, as of the end of each fiscal quarter of Borrower, a Consolidated Funded Debt to EBITDA Ratio, equal to or less than 2.5 to 1.0.

(b) Minimum EBITDA. Maintain on a consolidated basis, as of the end of each fiscal quarter of Borrower, for the period of the four prior fiscal quarters ending on such date, Consolidated EBITDA equal to or greater than Thirty Million Dollars (\$30,000,000).

(d) Amendments to Section 9.17. In the first sentence of subsection (b) of Section 9.17, the reference to “JAMS/ENDISPUTE, LLC, a Delaware limited liability company or any successor thereof” is amended and restated to be a reference to

“American Arbitration Association or any successor thereof” and the definition of and each reference to the term “JAMS” is amended and restated to be a reference to “AAA.”

3. Amendments to Note. In the heading of the Note, the reference to the amount of \$10,000,000 is amended and restated to be a reference to the amount of \$25,000,000 and in the first

3

paragraph of the Note, the reference to the amount of Ten Million Dollars (\$10,000,000) is amended and restated to be a reference to the amount of Twenty-five Million Dollars (\$25,000,000).

4. Conditions to Effectiveness. Notwithstanding anything contained herein to the contrary, this Amendment shall become effective when each of the following conditions is fully and simultaneously satisfied; provided that each such condition is fully and simultaneously satisfied on or before May 30, 2006:

(a) Delivery of Amendment. Borrower and Bank shall have executed and delivered counterparts of this Amendment to each other;

(b) Payment of Fees. Borrower shall have paid to Bank an amendment fee in the amount of Twenty-five Thousand Dollars (\$25,000) in respect of Bank’s agreement to enter into this Amendment;

(c) Confirmation of Guarantors. Each Guarantor shall have executed and delivered to Bank a Consent of Guarantors in the form of Annex 1 hereto;

(d) Representations True; No Default. The representations of Borrower as set forth in Article V of the Credit Agreement shall be true on and as of the date of this Amendment with the same force and effect as if made on and as of this date or, if any such representation or warranty is stated to have been made as of or with respect to a specific date, as of or with respect to such specific date. No Event of Default and no event which, with notice or lapse of time or both, would constitute an Event of Default, shall have occurred and be continuing or will occur as a result of the execution of this Amendment; and

(e) Other Documents. Bank shall have received such other documents, instruments, and undertakings as Bank may reasonably request.

5. Representations and Warranties. Borrower hereby represents and warrants to Bank that each of the representations and warranties set forth in Article V of the Credit Agreement is true and correct as if made on and as of the date of this Amendment or, if any such representation or warranty is stated to have been made as of or with respect to a specific date, as of or with respect to such specific date. Borrower expressly agrees that it shall be an additional Event of Default under the Credit Agreement if any representation or warranty made by the Borrower hereunder shall prove to have been incorrect in any material respect when made.

6. No Further Amendment. Except as expressly modified by this Amendment, the Credit Agreement and the other Loan Documents shall remain unmodified and in full force and effect and the parties hereby ratify their respective obligations thereunder.

7. Reservation of Rights. Borrower acknowledges and agrees that the execution and delivery by Bank of this Amendment shall not be deemed to create a course of dealing or otherwise obligate Bank to forbear or execute similar amendments under the same or similar circumstances in the future.

8. Miscellaneous.

(a) Governing Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF WASHINGTON; PROVIDED THAT BANK SHALL RETAIN ALL RIGHTS ARISING UNDER FEDERAL LAW.

(b) Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

4

(c) Integration. This Amendment, together with the other Loan Documents, comprises the complete, final and integrated agreement of the parties on the subject matter hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter.

(d) Severability. Any provision of this Amendment that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions thereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

(e) Oral Agreements. **ORAL AGREEMENTS OR ORAL COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER WASHINGTON LAW.**

IN WITNESS WHEREOF, Borrower and Bank have caused this Amendment to be duly executed as of the date first above written.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller
Name: Gilbert A. Fuller
Title: Exec. Vice Pres. and CFO

BANK OF AMERICA, N.A.

By: /s/ Mark N. Crawford
Name: Mark N. Crawford
Title: Senior Vice President

CONSENT OF GUARANTORS

This CONSENT OF GUARANTORS (this "Consent") is entered into as of May 17, 2006, by USANA ACQUISITION CORP., a Utah corporation ("USANA Acquisition"), WASATCH PRODUCT DEVELOPMENT, INC., a Utah corporation ("Wasatch"), USANA HEALTH SCIENCES NEW ZEALAND, INC., a Delaware corporation ("USANA New Zealand"), USANA CANADA HOLDING, INC., a Delaware corporation ("USANA Canada"), FMG PRODUCTIONS, INC., a Utah corporation ("FMG"), INTERNATIONAL HOLDINGS, INC., a Delaware corporation ("Holdings" and together with USANA Acquisition, Wasatch, USANA New Zealand, USANA Canada, FMG and their respective successors, collectively, the "Guarantors" and individually, a "Guarantor"), for the benefit of BANK OF AMERICA, N.A., a national banking association (together with its successors and assigns, "Bank").

RECITALS

A. USANA HEALTH SCIENCES, INC., a Utah corporation (together with its successors, "Borrower"), and Bank are parties to that certain Credit Agreement dated as of June 16, 2004, as amended by that certain Waiver and Amendment to Credit Agreement dated as of February 2, 2006 (as the same may be amended, modified or extended from time to time the "Credit Agreement"). Capitalized terms not otherwise defined in this Amendment shall have the meanings given in the Credit Agreement.

B. In connection with and as a condition to the obligation of Bank to make its initial Credit Extension under the Credit Agreement, each Guarantor entered into that certain Continuing Guaranty dated as of June 16, 2004 (as amended, restated, extended, supplemented or otherwise modified from time to time, the "Guaranty"), pursuant to which each Guarantor guaranteed, among other things, the payment and performance of the debts, liabilities, obligations, covenants and duties of, Borrower to Bank arising under the Credit Agreement and the other Loan Documents.

C. Borrower and Bank intend to enter into that certain Amendment to Credit Agreement dated as of May 17, 2006 (the "Amendment"), pursuant to which Bank will increase the amount of the revolving line of credit made available to Borrower under the Credit Agreement to \$25,000,000, extend its termination to May 30, 2011 and to make certain other modifications to the Credit Agreement.

D. It is a condition precedent to the effectiveness of the Amendment that each Guarantor enter into this Consent.

NOW THEREFORE, in consideration of the foregoing, and for other good and valuable consideration receipt of which is hereby acknowledged, each Guarantor agrees as follows:

AGREEMENT

1. **Consent.** Each Guarantor hereby acknowledges that it has received a copy of the Amendment and hereby consents to its contents, including all prior and current amendments to the Credit Agreement (notwithstanding that such consent is not required).

2. **Ratification and Confirmation.** Each Guarantor hereby ratifies and confirms each of its debts, liabilities, obligations, covenants and duties to Bank arising under the Guaranty and the other Loan Documents to which such Guarantor is a party. Each Guarantor hereby confirms that its guarantee of the payment and performance of the Guaranteed Obligations (as defined in the Guaranty) remains in full force and effect, and that the Guaranteed Obligations (as defined in the Guaranty) shall include the debts, liabilities, obligations, covenants and duties of, Borrower to Bank arising under the Credit Agreement and the other Loan Documents as amended by the Amendment and the documents, instruments and agreements contemplated thereby.

1

3. **Representations and Warranties.** Each Guarantor hereby represents and warrants to Bank that each of the representations and warranties set forth in Section 28 of the Guaranty Agreement is true and correct as if made on and as of the date of this Consent.

4. **Governing Law.** THIS CONSENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF WASHINGTON; PROVIDED THAT BANK SHALL RETAIN ALL RIGHTS ARISING UNDER FEDERAL LAW.

5. **Severability.** Any provision of this Consent that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions thereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

6. **Oral Agreements.** ORAL AGREEMENTS OR ORAL COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER WASHINGTON LAW.

IN WITNESS WHEREOF, each Guarantor has caused this Consent to be duly executed as of the date first above written.

USANA ACQUISITION CORP.

By: /s/ Gilbert A. Fuller
Name: Gilbert A. Fuller
Title: Treasurer

WASATCH PRODUCT DEVELOPMENT, INC.

By: /s/ Gilbert A. Fuller
Name: Gilbert A. Fuller
Title: Treasurer

USANA HEALTH SCIENCES NEW ZEALAND, INC.

By: /s/ Gilbert A. Fuller
Name: Gilbert A. Fuller
Title: Treasurer

2

USANA CANADA HOLDING, INC.

By: /s/ Gilbert A. Fuller
Name: Gilbert A. Fuller
Title: Secretary

FMG PRODUCTIONS, INC.

By: /s/ Gilbert A. Fuller
Name: Gilbert A. Fuller
Title: V.P. and Treasurer

INTERNATIONAL HOLDINGS, INC.

By: /s/ Mitchell Walkington
Name: Mitchell Walkington
Title: Secretary and Treasurer

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, Myron W. Wentz, Chief Executive Officer of USANA Health Sciences, Inc., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. (the "Registrant");
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Quarterly Report;
4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and
 - d) disclosed in this Quarterly Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the the Registrant's internal control over financial reporting.

Date: August 8, 2006

/s/ Myron W. Wentz
Myron W. Wentz, PhD
Chief Executive Officer
(Principal Executive Officer)

CHIEF FINANCIAL OFFICER CERTIFICATION

I, Gilbert A. Fuller, Chief Financial Officer of USANA Health Sciences, Inc., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. (the "Registrant");
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Quarterly Report;
4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and
 - d) disclosed in this Quarterly Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the the Registrant's internal control over financial reporting.

Date: August 8, 2006

/s/ Gilbert A. Fuller

Gilbert A. Fuller

Chief Financial Officer

(Principal Accounting and Financial Officer)

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned hereby certifies that the Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. for the quarter ended July 1, 2006 as filed August 8, 2006 with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of The Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of USANA Health Sciences, Inc.

Date: August 8, 2006

/s/ Myron W. Wentz

Myron W. Wentz, PhD
Chairman and Chief Executive Officer
(Principal Executive Officer)

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned hereby certifies that the Quarterly Report on Form 10-Q of USANA Health Sciences, Inc. for the quarter ended July 1, 2006 as filed August 8, 2006 with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of The Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of USANA Health Sciences, Inc.

Date: August 8, 2006

/s/ Gilbert A. Fuller

Gilbert A. Fuller

Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
